Literature DB >> 30218247

Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?

Jun-Xi Xiang1, Xu-Feng Zhang1, Eliza W Beal2, Matthew Weiss3, Luca Aldrighetti4, George A Poultsides5, Todd W Bauer6, Ryan C Fields7, Shishir Kumar Maithel8, Hugo P Marques9, Timothy M Pawlik10,11.   

Abstract

OBJECTIVES: The objective of this study was to assess the impact of unresected primary tumor, as well as extrahepatic metastasis, on the long-term prognosis of patients undergoing hepatic resection for non-functional neuroendocrine liver metastasis (NF-NELM).
METHODS: Patients who underwent hepatic resection for NF-NELM were identified from a multi-institutional database. Data on clinical and pathological details, as well as the long-term overall survival (OS) were obtained and compared. Propensity score matching was performed to generate matched pairs of patients.
RESULTS: Among the 332 patients with NF-NELM, 281 (84.6%) underwent primary tumor resection, while 51 (15.4%) did not. Patients who underwent primary resection were more likely to have a pancreatic primary and metachronous NELM. The long-term OS of patients who did and did not have the primary neuroendocrine tumor (NET) resected was comparable on both unmatched (10-year survival rate 66.8% vs. 54.0%, p = 0.192) and matched (10-year survival rate 75.7% vs. 60.4%, p = 0.271) analyses. In contrast, patients with NF-NELM and extrahepatic metastasis had a worse OS following resection compared with patients who had intrahepatic-only metastasis on unmatched (10-year survival rate 37.5% vs. 69.3%, p = 0.002) and matched (10-year survival rate 37.5% vs. 86.3%, p = 0.011) analyses. On multivariable analysis, while resection of the primary NET was not associated with OS (hazard ratio [HR] 0.7, 95% confidence interval [CI] 0.4-1.2, p = 0.195), the presence of extrahepatic metastasis was independently associated with long-term risk of death (HR 3.9, 95% CI 1.7-9.2, p = 0.002).
CONCLUSIONS: While surgery should be considered for patients with NF-NELM who have an unresectable primary tumor, operative resection of NF-NELM may not be as beneficial in patients with extrahepatic disease.

Entities:  

Mesh:

Year:  2018        PMID: 30218247     DOI: 10.1245/s10434-018-6751-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

2.  Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

3.  Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases.

Authors:  Steven D Scoville; Dimitrios Xourafas; Aslam M Ejaz; Allan Tsung; Timothy Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Surg       Date:  2020-04-27

4.  Surgical treatment for neuroendocrine liver metastasis: moving ahead in controversy.

Authors:  Jun-Xi Xiang; Yi Lv; Xu-Feng Zhang
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

5.  Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.

Authors:  Shinsei Yumoto; Shigeki Nakagawa; Hiromitsu Hayashi; Daisuke Ogawa; Yuta Shiraishi; Hiroki Sato; Takashi Matsumoto; Katsunori Imai; Yo-Ichi Yamashita; Hideo Baba
Journal:  Clin J Gastroenterol       Date:  2022-08-29

6.  Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification.

Authors:  Min Yang; Lin Zeng; Sheng-Zhong Hou; Neng-Wen Ke; Bo-le Tian; Xu-Bao Liu; Bo Xiang; Yi Zhang
Journal:  J Oncol       Date:  2020-09-15       Impact factor: 4.375

Review 7.  Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review.

Authors:  Yijun Xia; Lei Zhang; Huijun Wu; Liang Qiao; Long Xia
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 8.  Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.

Authors:  Alexander R Siebenhüner; Melanie Langheinrich; Juliane Friemel; Niklaus Schäfer; Dilmurodjon Eshmuminov; Kuno Lehmann
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.